ERBB2 and neoplasm: We demonstrated that RAD201 has a favorable biodistribution, with a high target-to-background ratio and a high level of accumulation at all active HER2-positive tumor sites, including visceral foci, lymph nodes, and skeletal and intracranial lesions.